A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ
Table 3
Univariate and multivariate analysis of the associations between baseline clinical-, histopathological-, and molecular characteristics and the risk for a recurrence being invasive carcinoma compared to in situ carcinoma, among women with a primary DCIS and a known recurrence in the Uppsala/Västerås cohort, in the SweDCIS randomized study and in the two groups pooled together ().
Risk of a recurrence after DCIS being invasive compared to a new in situ
U/V cohort ()
SweDCIS ()
All DCIS with a recurrence ()
Univariate* OR (95% CI)
Multivariate† OR (95% CI)
Univariate* OR (95% CI)
Multivariate† OR (95% CI)
Univariate* OR (95% CI)
Multivariate† OR (95% CI)
Mode of detection
Screening
1.0
1.0
1.0
1.0
1.0
1.0
Clinically
1.82 (0.66–5.08)
1.83 (0.61–5.5)
1.64 (0.83–3.27)
1.71 (0.85–3.46)
1.72 (0.98–3.01)
1.80 (1.02–3.19)
Tumor size
≤15 mm
1.0
1.0
1.0
1.0
1.0
1.0
>15 mm or multifocal
0.31 (0.12–0.84)
0.32 (0.11–0.93)
0.84 (0.41–1.63)
0.84 (0.32–1.57)
0.55 (0.33–0.93)
0.54 (0.32–0.92)
Type of surgery
Breast conserving surgery
1.0
—
—
—
1.0
—
Mastectomy
0.88 (0.20–3.88)
—
—
—
1.13 (0.29–4.42)
—
Postoperative radiotherapy
No
1.0
1.0
1.0
1.0
1.0
1.0
Yes
0.95 (0.39–2.34)
1.27 (0.46–3.56)
1.59 (0.80–3.20)
1.70 (0.83–3.46)
1.32 (0.76–2.27)
1.41 (0.80–2.48)
Free margins
Yes
1.54 (0.28–8.36)
—
0.93 (0.41–2.13)
1.24 (0.69–2.22)
—
No or doubtful
1.0
—
1.0
1.0
—
Nuclear grade
I
1.0
1.0
1.0
1.0
1.0
1.0
II
1.37 (0.35–5.4)
1.23 (0.29–5.15)
0.21 (0.02–1.87)
0.20 (0.02–1.81)
0.75 (0.26–2.12)
0.70 (0.25–2.02)
III
1.58 (0.41–6.06)
1.55 (0.38–6.37)
0.12 (0.02–1.02)
0.11 (0.01–0.96)
0.53 (0.19–1.45)
0.49 (0.18–1.35)
ER
Negative
1.0
1.0
1.0
1.0
1.0
1.0
Positive
2.23 (0.86–5.78)
2.29 (0.87–6.03)
2.54 (0.91–7.10)
3.34 (1.10–10.2)
2.33 (1.17–4.65)
2.52 (1.24–5.10)
PR
Negative
1.0
1.0
1.0
1.0
1.0
1.0
Positive
1.03 (0.45–2.38)
1.03 (0.44–2.39)
1.83 (0.76–4.42)
2.20 (0.83–5.40)
1.32 (0.73–2.38)
1.36 (0.75–2.47)
HER2
Negative
1.0
1.0
1.0
1.0
1.0
1.0
Positive
0.55 (0.23–1.30)
0.60 (0.24–1.47)
0.46 (0.19–1.11)
0.42 (0.17–1.07)
0.50 (0.27–0.92)
0.48 (0.26–0.90)
EGFR
Negative
1.0
1.0
1.0
1.0
1.0
1.0
Positive
0.35 (0.13–0.92)
0.36 (0.13–0.98)
0.62 (0.23–1.64)
0.57 (0.21–1.58)
0.45 (0.23–0.88)
0.44 (0.22–0.88)
Ki67
Low
1.0
1.0
1.0
1.0
1.0
1.0
High
1.10 (0.41–2.97)
1.09 (0.38–3.12)
1.03 (0.38–2.82)
1.10 (0.38–3.19)
0.98 (0.50–1.94)
0.93 (0.46–1.85)
Subgroups based on IHC
ER+/HER2−
1.0
1.0
1.0
1.0
1.0
1.0
ER+/HER2+
1.15 (0.35–3.77)
1.27 (0.37–4.39)
0.64 (0.21–2.02)
0.64 (0.20–2.02)
0.84 (0.37–1.89)
0.83 (0.37–1.88)
ER−/HER2+
0.25 (0.07–0.93)
0.26 (0.07–0.98)
0.30 (0.08–1.12)
0.22 (0.05–0.95)
0.27 (0.11–0.68)
0.24 (0.09–0.62)
**ER−/HER2−/CK5/6+ or EGFR+
0.42 (0.09–1.99)
0.41 (0.08–0.98)
0.75 (0.13–4.20)
0.75 (0.13–4.30)
0.54 (0.17–1.71)
0.52 (0.16–1.65)
Unknown
1.68 (0.46–6.17)
1.62 (0.43–6.12)
0.70 (0.33–1.48)
0.70 (0.33–1.48)
0.75 (0.42–1.34)
0.76 (0.42– 1.35)
Adjustments for age group. †Adjustments for age group, free margin, and type of surgery. **We used the classification for basal-like DCIS published by Livasy et al., 2007 [22], and also used in an earlier paper by us [37].
